270 related articles for article (PubMed ID: 26554946)
1. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
2. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
3. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
4. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Zheleva DI; McInnes C; Gavine AL; Zhelev NZ; Fischer PM; Lane DP
J Pept Res; 2002 Nov; 60(5):257-70. PubMed ID: 12383116
[TBL] [Abstract][Full Text] [Related]
5. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
6. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
Andrews MJ; Kontopidis G; McInnes C; Plater A; Innes L; Cowan A; Jewsbury P; Fischer PM
Chembiochem; 2006 Dec; 7(12):1909-15. PubMed ID: 17051658
[TBL] [Abstract][Full Text] [Related]
7. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.
Canela N; Orzáez M; Fucho R; Mateo F; Gutierrez R; Pineda-Lucena A; Bachs O; Pérez-Payá E
J Biol Chem; 2006 Nov; 281(47):35942-53. PubMed ID: 17001081
[TBL] [Abstract][Full Text] [Related]
8. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
9. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
McInnes C; Andrews MJ; Zheleva DI; Lane DP; Fischer PM
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):57-69. PubMed ID: 12678915
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
13. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.
Moshinsky DJ; Bellamacina CR; Boisvert DC; Huang P; Hui T; Jancarik J; Kim SH; Rice AG
Biochem Biophys Res Commun; 2003 Oct; 310(3):1026-31. PubMed ID: 14550307
[TBL] [Abstract][Full Text] [Related]
14. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
Liu S; Bolger JK; Kirkland LO; Premnath PN; McInnes C
ACS Chem Biol; 2010 Dec; 5(12):1169-82. PubMed ID: 20843055
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
17. Exploiting structural principles to design cyclin-dependent kinase inhibitors.
Noble M; Barrett P; Endicott J; Johnson L; McDonnell J; Robertson G; Zawaira A
Biochim Biophys Acta; 2005 Dec; 1754(1-2):58-64. PubMed ID: 16361058
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
20. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
